Neurolase Laser Therapy Substitute for VIOXX^TM

BioTech Medics through its merger with HaloLaser is a member of

    WORLD ASSOCIATION FOR LASER THERAPY

In a recent WALT Press Release - Laser Therapy has proven to be an effective

substitute for "VIOXX" in some arthritic cases with NO ADVERSE SIDE EFFECTS! 

In the Dec 4th paper issue of the British Medical Journal, a new meta analysis on the effect of NSAIDs on knee osteoarthritis pain appears, that may become important to the recognition of laser therapy worldwide.

"Adverse events of long term medication with NSAIDs and particularly coxibs, has recently received much attention in the Vioxx-matter. Consequently, coxibs like Vioxx has been withdrawn and Prexige has been withheld from the market, and the whole group of coxibs, are now under special observation by drug agencies in both Europe and the United States.

In contrast to the virtually non-existent side-effects of laser therapy, NSAID side-effects cause an estimated number of 2000 deaths annually in Great Britain alone, because half of the 8.5 million osteoarthritis patients there take these drugs on a regular basis. The recent development is further moving the balance in disfavour of NSAIDs and coxibs, and may well be the end of the era where they served as reference treatment for osteoarthritis.

The current situation may pave the road for other risk-free alternatives such as laser therapy, which has appeared to provide clinically relevant changes in several randomised placebo-controlled trials.

From the findings of a recent Norwegian Health Technology Assessment Report, laser therapy was given potential of becoming at least twice as effective as NSAIDs, if applied with optimal dose and energy (> 2.5 Joule per point for 810-30 nm, and > 0.6 Joules per point for 904 nm, and at least 3 points irradiated). Although the number of laser trials is still smaller than for NSAIDs, the unequivocal scientific findings so far, has earned laser therapy a top spot in levels of evidence and treatment recommendations for knee osteoarthritis issued by the Norwegian Drug Agency.

Laser therapy is also reimbursed in the physiotherapy program of the National Health Insurance Agency, and is slowly becoming one of the standard therapies for knee osteoarthritis pain in Norway."

Medicare will pay for those who are eligible for the physician's office visits (less any applicable deductible) in the USA.  The Neurolase in the USA is for temporarily treating muscle and/or skeletal pain associated with arthritis.  Numerous treatments are required for arthritic relief.  Each patient will have a unique response to the treatment.